225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer

• Verfasst von: Kratochwil, Clemens [VerfasserIn]
• Verfasst von: Giesel, Frederik L. [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Titel: 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer
• Verf.angabe: Clemens Kratochwil, Frank Bruchertseifer, Frederik L. Giesel, Mirjam Weis, Frederik A. Verburg, Felix Mottaghy, Klaus Kopka, Christos Apostolidis, Uwe Haberkorn, and Alfred Morgenstern
• Umfang: 4 S.
• Fussnoten: Gesehen am 07.11.2017
• Titel Quelle: Enthalten in: Journal of nuclear medicine
• Jahr Quelle: 2016
• Band/Heft Quelle: 57(2016), 12, S. 1941-1944
• ISSN Quelle: 2159-662X
• ISSN Quelle: 1535-5667
• DOI: doi:10.2967/jnumed.116.178673
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1565078861

Abstract

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy. Methods: 68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. Results: Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. Conclusion: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.